[5] Incyte Corporation currently develops and manufacturers prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity.

[7] In September 2015, the company announced it had gained exclusive development and commercial right pertaining to Jiangsu Hengrui Medicine Co., Ltd's anti-PD-1 monoclonal antibody, SHR-1210, in a deal worth $795+ million.

[8] In January 2020, Incyte signed a collaboration and license agreement for the global development and commercialization of tafasitamab with MorphoSys.

[14] As of 2014, the company was developing baricitinib, an oral JAK1 and JAK2 inhibitor drug for rheumatoid arthritis in partnership with Eli Lilly.

[20][21] As of 2016 epacadostat, an indoleamine 2,3-dioxygenase (IDO1) inhibitor, was in development for various cancers and was in combination trials with Merck's pembrolizumab (Keytruda) and Bristol Myers Squibb's nivolumab (Opdivo).